PCN22 Cost-Effectiveness of Pembrolizumab PLUS Axitinib Versus Nivolumab PLUS Ipilimumab As First-LINE Treatment of Advanced Renal CELL Carcinoma

Line Treatment ◽

First Line ◽

Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma

Current Medical Research and Opinion ◽

10.1080/03007995.2020.1799771 ◽

2020 ◽

Vol 36 (9) ◽

pp. 1507-1517

Author(s):

Arielle G. Bensimon ◽

Yichen Zhong ◽

Umang Swami ◽

Allison Briggs ◽

Joshua Young ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma

Value in Health ◽

10.1111/j.1524-4733.2009.00617.x ◽

2010 ◽

Vol 13 (1) ◽

pp. 61-68 ◽

Cited By ~ 23

Author(s):

Martin Hoyle ◽

Colin Green ◽

Jo Thompson-Coon ◽

Zulian Liu ◽

Karen Welch ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.01.009 ◽

2021 ◽

Author(s):

Rebecca Shay ◽

Andrew Nicklawsky ◽

Dexiang Gao ◽

Elaine T. Lam

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Renal Cell ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US

JAMA Network Open ◽

10.1001/jamanetworkopen.2020.16144 ◽

2020 ◽

Vol 3 (10) ◽

pp. e2016144

Author(s):

Tina R. Watson ◽

Xin Gao ◽

Kerry L. Reynolds ◽

Chung Yin Kong

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

The Us ◽

PCN94 - COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK

Value in Health ◽

10.1016/j.jval.2018.09.176 ◽

2018 ◽

Vol 21 ◽

pp. S30 ◽

Cited By ~ 1

Author(s):

E. Skentzou ◽

J. Meng ◽

J. Lister ◽

L. Gray

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

The Uk ◽

PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE

Value in Health ◽

10.1016/j.jval.2019.09.410 ◽

2019 ◽

Vol 22 ◽

pp. S477

Author(s):

S. Branchoux ◽

S. Négrier ◽

C. de Peretti ◽

B. Malcolm ◽

J. May ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Renal Cell ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Annals of Oncology ◽

10.1093/annonc/mdz249.052 ◽

2019 ◽

Vol 30 ◽

pp. v386-v387

Author(s):

M. Uemura ◽

Y. Tomita ◽

H. Miyake ◽

S. Hatakeyama ◽

H.-O. Kanayama ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Subgroup Analysis ◽

Renal Cell ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2015.1058359 ◽

2015 ◽

Vol 16 (13) ◽

pp. 1915-1927 ◽

Cited By ~ 15

Author(s):

James Larkin ◽

Abby Paine ◽

Grace Foley ◽

Stephen Mitchell ◽

Connie Chen

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis ◽

Line Treatment ◽

First Line ◽

Correction to: “Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use”

Drugs & Therapy Perspectives ◽

10.1007/s40267-019-00613-z ◽

2019 ◽

Vol 35 (4) ◽

pp. 200-200

Author(s):

Katherine A. Lyseng-Williamson

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use

Drugs & Therapy Perspectives ◽

10.1007/s40267-018-0547-6 ◽

2018 ◽

Vol 34 (10) ◽

pp. 457-465 ◽

Cited By ~ 4

Author(s):

Katherine A. Lyseng-Williamson

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽